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Methods and processes for development of
a CONSORT extension for reporting pilot
randomized controlled trials
Lehana Thabane1*, Sally Hopewell2, Gillian A. Lancaster5, Christine M. Bond6, Claire L. Coleman3,
Michael J. Campbell4 and Sandra M. Eldridge3
Abstract
Background: Feasibility and pilot studies are essential components of planning or preparing for a larger
randomized controlled trial (RCT). They are intended to provide useful information about the feasibility of the main
RCT—with the goal of reducing uncertainty and thereby increasing the chance of successfully conducting the main
RCT. However, research has shown that there are serious inadequacies in the reporting of pilot and feasibility
studies. Reasons for this include a lack of explicit publication policies for pilot and feasibility studies in many
journals, unclear definitions of what constitutes a pilot or feasibility RCT/study, and a lack of clarity in the objectives
and methodological focus. All these suggest that there is an urgent need for new guidelines for reporting pilot and
feasibility studies.
Objectives: The aim of this paper is to describe the methods and processes in our development of an extension to
the Consolidated Standards of Reporting Trials (CONSORT) Statement for reporting pilot and feasibility RCTs, that
are executed in preparation for a future, more definitive RCT.
Methods/design: There were five overlapping parts to the project: (i) the project launch—which involved
establishing a working group and conducting a review of the literature; (ii) stakeholder engagement—which entailed
consultation with the CONSORT group, journal editors and publishers, the clinical trials community, and funders; (iii)
a Delphi process—used to assess the agreement of experts on initial definitions and to generate a reporting
checklist for pilot RCTs, based on the 2010 CONSORT statement extension applicable to reporting pilot studies; (iv)
a consensus meeting—to discuss, add, remove, or modify checklist items, with input from experts in the field; and
(v) write-up and implementation—which included a guideline document which gives an explanation and
elaboration (E&E) and which will provide advice for each item, together with examples of good reporting practice.
This final part also included a plan for dissemination and publication of the guideline.
Conclusions: We anticipate that implementation of our guideline will improve the reporting completeness,
transparency, and quality of pilot RCTs, and hence benefit several constituencies, including authors of journal
manuscripts, funding agencies, educators, researchers, and end-users.
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Background
Feasibility and pilot studies are essential components of
planning or preparing for a larger randomized controlled
trial (RCT). They are intended to provide useful infor-
mation about the feasibility of running the main RCT [1,
2] with the goal of reducing uncertainty and thereby in-
creasing the chance of successfully conducting the main
RCT. They are also useful preliminary studies that other
researchers can learn from when developing their own
study designs to enhance their approach or avoid similar
pitfalls. However, many journals do not have a specific
publication policy for these types of study or consider
them a priority, and it has been shown that there are
serious inadequacies in how pilot and feasibility studies
are reported [1–6]. First, the dearth of published re-
search describing pilot/feasibility studies suggests that
only a minority of them actually reach publication; add-
itionally, when they are published, a wide variety of
terms are used to describe them. Second, only a small
percentage of this minority of published pilot and feasi-
bility studies explicitly state that they are intended as
preparation for a larger RCT. Third, in many instances,
the objectives of pilot and feasibility studies are unclear
or are mis-specified as being the same as in the main
RCT. Lastly, methodological features of pilot and feasi-
bility studies are often inappropriately reported in the
same format as in the main RCT. Reasons for these defi-
ciencies include not only the lack of explicit publication
policies for pilot and feasibility studies in many journals
[3, 4] but also unclear definitions of what actually consti-
tutes a pilot or feasibility RCT/study [2, 6] and confu-
sion about what the objectives and methodological focus
ought to be in such studies [1–3]. All these suggest that
there is an urgent need for the development of new
guidelines for reporting of pilot and feasibility studies.
Given the importance of these studies in preparing for
future definitive trials, we anticipate that the guideline
will help to address the prevailing flaws in their conduct
and reporting, leading to superior-quality pilot trials and
enhanced feasibility for the main RCTs.
Initial discussions on developing reporting guidelines
for feasibility and pilot studies occurred at the annual
scientific meeting of the Society for Academic Primary
Care (SAPC) held in Bristol (UK) on June 6–8, 2011,
during a workshop on “Pilot and feasibility studies:
How best to obtain pre-trial information and publish
it”, organized and led by Sandra Eldridge, Gillian Lan-
caster, and Sally Kerry and attended by Christine Bond.
The workshop was intended to clarify the aims of pilot
and feasibility studies, improve understanding of the
particular requirements of these studies (including spe-
cification of their key objectives), and discuss how to
report them appropriately. It was proposed (after the
workshop) that reporting guidelines for feasibility and
pilot studies would be helpful as a template for re-
searchers, reviewers, and editors to use when preparing
or reviewing papers for publication; they would also
provide guidance to funders and policy-makers who
review grant or funding proposals for feasibility and
pilot studies.
Arising from this workshop, SE, GL, and CB engaged
other collaborators in the area (MJC, LT, SH), and the
group embarked together on a programme of research
focusing on the reporting of feasibility and pilot studies.
This paper reports part of that work: the methods and
processes used in the development of a consolidated stan-
dards of reporting trials (CONSORT) extension guideline
for reporting randomized pilot and feasibility studies. The
guideline focuses on reporting of pilot and feasibility
RCTs, using the 2010 CONSORT Statement [7] as the
starting point. The original CONSORT guideline aimed to
improve the reporting of two-arm parallel group RCTs [8]
and was later extended to cover other types of designs:
cluster randomized trials [9], non-inferiority and equiva-
lence trials [10], pragmatic trials [11], and N-of-1 trials
[12]. A variety of clinical areas has also been discussed, in-
cluding the following interventions: herbal medicinal [13],
non-pharmacological [14], and acupuncture [15]. Finally,
related types of data have been described, including the
following: patient-reported outcomes [16], harms [17],
abstracts [18], and RCT protocols [19].
Aims
The aim of this paper is to describe the methods and
processes for development of our CONSORT exten-
sion for reporting feasibility and pilot RCTs that are
executed in preparation for a future definitive large-
scale RCT. Reporting guidance for other types of pilot
and feasibility studies—which include non-randomized
and qualitative pilot and feasibility studies—will be a
focus of future work.
Methods and processes
We followed previously recommended methods and pro-
cesses for developing, disseminating, and implementing
consensus reporting guidelines [20–22]. Briefly, these in-
cluded a series of activities: (1) project launch—which in-
cluded establishing the working group, identifying the
need for the guideline, performing a literature review of
current practice, and drafting an initial list of items and
starting to seek funding support for the project; (2) en-
gagement with stakeholders—which included identifying
potential participants for a Delphi study and face-to-face
consensus meeting and early presentations of potential
items to gain feedback at conferences and workshops; (3)
conducting the Delphi study, including a pilot Delphi
and set-up of the questions online and presentation of
the results at a methodology meeting of trialists; (4) a
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consensus meeting, to present the results of the literature
review and the Delphi study and to discuss the revised
list of checklist items; (5) write-up and implementation
including creating the guideline, addressing feedback
from users, establishing the explanation and elaboration
(E&E) document, and devising a publication strategy; and
(6) post-publication activities—which covers encouraging
guideline uptake and endorsement, updating the guideline,
and evaluating impact. These methods or their varia-
tions and adaptations have been used in development
of other similar guidelines [7, 9–20]. Figure 1 illus-
trates the five parts of the development process for
this guideline: (i) the project launch, (ii) stakeholder
engagement, (iii) a modified Delphi process, (iv) a
consensus meeting, and (v) write-up and implementa-
tion. It does not yet include post-publication activities
where we will engage in dissemination and endorse-
ment, as we have not yet reached this stage. The de-
velopment process is described below. But it should
be noted, however, that the process was iterative—re-
peating some part(s) as necessary—rather than linear.
Part 1: project launch
Establishing a working group
After the SAPC meeting in June 2011, our (SE, GL,
CB) first step was to establish a working group to
lead the process of developing the reporting guide-
lines. The core makeup of the group included people
with experience in conducting and publishing meth-
odological work on pilot and feasibility RCTs (CB,
SE, GL, LT, MC) and methodologists and statisti-
cians with expertise in the design and reporting of
RCTs and in reviewing funding or ethics applications
(SE, GL, LT, MC). A member of the CONSORT
group (SH) was invited and agreed to join the group
during the Delphi process. The group communicated
regularly throughout the process via a number of
face-to-face and virtual meetings (by teleconference
or Skype) and email discussions. CC joined the
group when she was appointed to a National Insti-
tute of Heath Research (NIHR) research methods
fellowship focusing on pilot studies supervised by SE
in 2013.
2013
Fig. 1 Development of the CONSORT extension to pilot trials guideline
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Review of the literature
We first reviewed the literature to assess the quality of
pilot and feasibility studies that had been published in
major medical journals (Lancet, the BMJ, the New Eng-
land Journal of Medicine, JAMA). These are amongst
the leading medical journals that have been included in
previous systematic reviews or surveys of the reporting
of pilot studies [1, 3]. We included articles identified in
the searches by Lancaster et al. [1] and Arain et al. [3],
as well as examples used in previous workshops con-
ducted by some of the working group members. We
assessed whether clear statements had been made with
respect to the following: whether the article concerned a
pilot or feasibility study; feasibility objectives; and
whether they stated that the feasibility or pilot study was
in preparation for a larger RCT. We also reviewed exist-
ing definitions of and reporting guidelines for pilot and
feasibility studies [1, 2, 23].
Part 2: stakeholder engagement
We engaged several groups of stakeholders in the process:
The CONSORT group: As noted earlier, the guideline
was developed with involvement of the CONSORT
group. As with other CONSORT-related guidelines,
the inclusion of a CONSORT Group member (SH)
was intended to ensure consistency in the use of recom-
mended methods in the development, dissemination, and
implementation of high quality reporting guidelines [24].
Clinical Trials Community: Our first engagement of
the clinical trials community was at the Annual
Meeting of the Society for Clinical Trials in Boston in
May 2012, where we presented early work from the
Delphi study (see later). This was organized as an
invited session at the meeting, and there were about 40
attendees. The presentation focused on problems in the
reporting of pilot and feasibility studies and the need to
develop guidance to improve the situation [25].
A second opportunity to engage a larger clinical trials
community was at the 2nd Clinical Trials Methodology
Conference in November 2013 in Edinburgh, Scotland.
This was an open session, and the discussion focused
mainly on the definitions of pilot and feasibility studies
(see “Part 3: the Delphi process” section later).
Over the course of the project, we have also delivered
a number of workshops and talks on feasibility and pilot
studies and sought feedback from the research commu-
nity. Overall, the reactions have supported the idea of
developing a CONSORT-type reporting guidelines for
feasibility and pilot studies. We recognize that there are
differences of opinion about the definitions of these
studies, particularly as they reflect various user groups
and theoretical perspectives, as we report elsewhere [26].
Journal Editors and Publishers: We engaged editors of
prominent journals known to published pilot and
feasibility studies including the BMJ Open, Journal of
Clinical Epidemiology, Clinical Trials, and BMC Trials.
The selection of the journal editors was pragmatic: (i)
our knowledge of publication of pilot and feasibility
studies led us to believe that these journal editors
would be interested in the work; (ii) the working group
members were already serving on the editorial boards
of some of these journals and had sent out personal
invitations to the editors; and (iii) these editors were
available to attend the consensus meeting. We also
engaged several publishers including BioMed Central
and the BMJ. We will continue to engage other journal
editors and publishers to ensure wider awareness and
endorsement of our guideline upon their completion. It
has been shown that formal endorsement of a guideline
by journals is a strong determinant of its adoption and
subsequent adherence to it [27].
Funders: We approached several funding agencies,
including the Medical Research Council UK, the
Canadian Health Research Institutes, and the Chief
Scientist Office, Scottish Government, to engage them
in providing financial support for the development of
the guideline. These are amongst the major agencies
that have financially supported pilot studies through
the national or international funding competitions. Our
own project was subsequently funded in part by the
Queen Mary University of London, the University of
Sheffield, the Chief Scientist Office in Scotland, the
NIHR Research Design Services London and South
East and the NIHR Statisticians Network.
The project was registered on the Enhancing the QUAlity
and Transparency Of health Research (EQUATOR) Net-
work website [28].
Part 3: the Delphi process
The Delphi process is iterative and provides a structured
collection of input, information, and feedback from partic-
ipants by using a series of survey questionnaires. Typically,
each questionnaire is refined based on comments from
previous iterations [29]. Generally considered to be one of
the central features in developing reporting guidelines [21,
22], the Delphi method has been widely used in this way
[7, 9–20]. The objectives of our Delphi process were (a) to
evaluate the agreement of the various participants (ap-
proximately 100 stakeholders in total, including trialists,
methodologists, and statisticians) with respect to our ini-
tial definitions of feasibility and pilot studies; (b) to assess
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their agreement on two reporting checklists, one for pilot
studies and the other for feasibility studies (see rationale
below), with the initial items being based on the current
(2010) CONSORT Statement [7]; (c) to elicit any further
items or changes to items that the participants thought
might be important; and (d) to identify which items the
Delphi participants felt were the most important. We re-
ceived research ethics approval for the Delphi study from
the University of Sheffield Research Ethics Committee.
Personal networks allowed us to identify individual
participants who were involved in, or interested in, pilot
and feasibility studies. We also sent invitations to people
on contact lists of the following: Canadian Institutes of
Health Research, the Biostatistics Section of the Statis-
tical Society of Canada, the American Statistical Society,
UK NIHR, Medical Research Council (MRC) Method-
ology Hubs, the International Society for Clinical Bio-
statistics, the UK Clinical Trials Units Network, the
Society for Clinical Trials, and the World Association of
Medical Editors.
Based on the literature review described earlier, the
current CONSORT Statement [7], and the mutually
exclusive definitions of pilot and feasibility studies
articulated by the UK National Institute of Health
Research, we created two versions of the checklis-
t—one for feasibility studies and the second for pilot
studies (Table 1).
The Delphi survey comprised three sections: partici-
pant demography, feedback on the NIHR and MRC defi-
nitions of feasibility and pilot studies [23, 26], and the
two checklist items (Table 1). The survey was produced
in an online format using CLINVIVO software and dis-
tributed through a weblink sent in an email.
The Delphi process was carried out between June and
October 2013. It was done in two phases. Phase 1 was the
pilot phase. We piloted the Delphi survey using a “think-
aloud” approach on 13 colleagues working at our own insti-
tutions. The purpose of this phase was to evaluate the ques-
tionnaire for face and content validity, usability, and clarity
of its items.
Phase 2 was the main Delphi study, which was con-
ducted in two rounds using an online survey con-
ducted by Clinvivo.
i. First round: We invited participants to declare an
interest in the study to Clinvivo by emailing
fapsdelphi@clinvivo.com. Clinvivo then replied by
sending a personalized link to the round. The round
opened on July 26, 2013 and closed on August 27,
2013. Invitations were sent to all those who had
expressed an interest up to and including August 26.
The two checklists are presented in Table 1. Most
items were identical or similar in the two lists. The
participants rated items on a nine-point scale,
ranging from 1 = “not at all appropriate” to 9
= “completely appropriate”. Participants could also
write comments under each rating (Fig. 2).
Overall, 93/100 participants responded to the online
survey. Table 2 provides a summary of the
demographic characteristics of the respondents.
ii.)2nd round: Participants who had completed the first
round were sent an email link to the second round on
September 24. Reminders to complete was sent on
October 7 and 14. The round closed on midnight, at
the International Date Line, on October 15.
In this round, participants were asked to review
tables of the scores of histograms of pilot and
feasibility items for which 70 % or more of the panel
had rated using the two highest appropriateness
scores (i.e. 8 and 9). They could then make additional
comments on these items. Participants were also
asked to review the remaining items that had been
rated slightly lower in terms of appropriateness, and
for each item, they were asked to indicate whether
they thought the item should be kept, discarded, or
whether they were unsure or had no opinion.
Participants were also asked whether they thought
any reporting aspects had been missed and should
be included in a checklist, and separately whether a
pilot study checklist would be suitable for phase I
studies, phase II studies, internal pilots, and external
pilots; and whether a feasibility checklist would be
suitable in the context of qualitative work, and what
they would regard as quantitative work. In each
case, participants could rate items as suitable,
unsure/no opinion, or not suitable. Finally,
participants could add comments on any other
aspects about the suitability of pilot and feasibility
study checklists. About 85 % (79/93) of the
respondents participated in the second round.
Overall, the Delphi results showed a strong agreement
on checklist items both for pilot and feasibility studies.
However, there was substantial disagreement about the
definitions of pilot and feasibility studies and the distinc-
tion between them.
At the Edinburgh meeting, we presented four proposi-
tions regarding definitions and preliminary Delphi results
[26]. The main outcome from the discussions was that
participants unanimously suggested that we should begin
by developing only one reporting checklist. At this stage,
it was unclear how wide the scope of this checklist
would be, though a strong steer from the meeting was
not to make it too wide.
Part 4: the consensus meeting
Prior to the consensus meeting: In February 2014, our
group had a face-to-face meeting in London, UK, to review
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Table 1 Drafts of the initial proposed checklists for feasibility and pilot studies
Item no.
(original CONSORT)
Feasibility studies Pilot studies
Abstract
1a Identification as feasibility study in title Identification as pilot in the title; randomized in title if used
1b Summary of study design, methods, results,
and conclusions
Summary of study design, methods, results, and conclusions
Background
2a Scientific background and explanation of rationale
for feasibility study
Scientific background and explanation of rationale for pilot study
2b Key aims and objectives of feasibility study Key aims and objectives of pilot study
2c Description of type of trial planning for
(e.g. drug development, health services,
community intervention, cluster trial, etc.)
Description of type of trial planning for
(e.g. drug development, health services,
community intervention, cluster trial, etc.)
Methods
3a1 Description of design of feasibility study covering
all objectives (may have several components addressing
different objectives which all need to be described);
adequate descriptions of how each objective is to be
addressed and any relevant thresholds for successful
implementation of component(s)
Description of design of pilot study (should differ from that
of main study because the aim is not to test effectiveness—thus,
data collected and types of analysis may differ); how differs from
main study; thresholds for success/proceeding to main trial
3a2 Description of criteria used to judge feasibility
(often a threshold, for example for recruitment rates)
Description of criteria used to judge whether to proceed with main trial
(often a threshold, for example for recruitment rates)
3b Important changes to methods, outcomes, eligibility criteria,
etc. during the study, with reasons
(changes are sometimes made during feasibility studies
because lack of feasibility is identified early on in a study)
Important changes to methods, outcomes, eligibility criteria,
etc. during the study, with reasons (changes are sometimes made
during pilot studies because a difficulty with a particular aspect is
identified fairly early on)
4a Specify how participants were selected for each component,
how many refused, if volunteers; eligibility criteria if any
Eligibility criteria for participants, how many refused; if cluster trial
pilot address issues around bias and contamination
4b Settings and locations where the data were collected Settings and locations where the data were collected
Description of how potential biases in the main trial are
being explored in the feasibility study (potential biases:
selection, detection, performance, attrition)
Description of how potential biases in the main trial are being explored
in the pilot study (potential biases: selection, detection, performance, attrition)
5a Detailed description of intervention to be tested in main trial,
specifying assessor, administration, duration, quality control
(e.g. calibration, training), etc. to be used in any
feasibility assessments
Detailed description of intervention being assessed in pilot study, i
ncluding assessor(s), control group if using, administration, duration,
quality control (e.g. calibration, training), etc. as appropriate
6a Specify assessments or measurements to be made to
address each objective, including how and when they
were made (each component of the study should be addressed);
include how feasibility of descriptive components will be addressed
Specify range of measurements to be taken including main outcome measure,
secondary outcome measures, if can be identified, recruitment and consent rates, etc.
6b Details of qualitative analysis if appropriate, cost-effectiveness Details of pre-trial modelling criteria
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Table 1 Drafts of the initial proposed checklists for feasibility and pilot studies (Continued)
7a Appropriate justification for sample size for each component
(unlikely to include a sample size calculation, more likely to
be a pragmatic decision)
Appropriate justification for sample size (does not need to include a formal
trial sample size calculation but may include other types of sample size calculations)
8a Details of administration of or qualitative work
related to randomisation
Method used to generate random allocation sequence (if randomized pilot study);
description of how it will be administered; details of any restrictions; who generated
the random allocation sequence, who enrolled participants, and who assigned
participants to interventions
11a If done, details of how blinding was considered and used If done, who was blinded, e.g. after assignment to interventions
(for example, participants, care providers, those assessing outcomes) and how
11b If relevant, description of how the interventions are to be
made similar and details of any testing done
If relevant, description of the similarity of interventions
12a Any statistical methods used in the analysis of each
component (if relevant)
Statistical methods used to summarize and compare groups for primary and
secondary outcomes; estimates of effect size with confidence intervals; no
hypothesis testing is recommended
12b Methods for additional analyses not addressing key objectives,
such as adjusted analyses and cost-effectiveness with justification
Methods for additional analyses not addressing key objectives, such as adjusted
analyses and cost-effectiveness with justification
Results
13a Description of participants and numbers for components
being assessed with flow diagram if appropriate
Description of participants and numbers for components being assessed
with flow diagram if appropriate; if randomisation used for each group, the
numbers of participants who were randomly assigned, received intended
treatment, and were assessed for the outcome(s)
13b Losses and exclusions for each component being tested,
including reasons
Losses and exclusions including reasons; if randomisation used for each group
14a Dates defining the periods of recruitment and follow-up
for each component
Dates defining the periods of recruitment and follow-up
14b Why recruitment to the study ended or was stopped prior
to the planned end of study (if relevant)
Why recruitment to the study ended or was stopped prior to the planned
end of study (if relevant)
15 Summary of people or samples used for each component tested A table showing baseline demographic and clinical characteristics for participants
in the study; if randomisation used for each group
16 For each component, number of participants (denominator)
or samples included in each analysis or data summary
For study participants and each group if randomized, number of participants
(denominator) included in each analysis or data summary; if randomized whether
the analysis was by original assigned groups
17a For all components tested ensure results match objectives;
if relevant estimated effect size and its precision
(such as 95 % confidence interval);
for binary outcomes, presentation of both absolute and r
elative effect sizes is recommended
For all parameters and outcomes tested ensure results match objectives; estimated
effect size and its precision (such as 95 % confidence interval); for binary outcomes,
presentation of both absolute and relative effect sizes is recommended
18 Results of any other analyses performed, including adjusted
analyses, distinguishing pre-specified from exploratory
Results of any other analyses performed, including subgroup analyses and
adjusted analyses, distinguishing pre-specified from exploratory
19 All important harms or unintended effects; detail and
discussion; patient questionnaires used to assess safety,
adverse events, harms, etc.
All important harms or unintended effects; detail and discussion; patient questionnaires
used to assess safety, adverse events, harms, etc.
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Table 1 Drafts of the initial proposed checklists for feasibility and pilot studies (Continued)
Discussion
20 Limitations addressing sources of potential bias,
changes to components, imprecision of estimates,
multiplicity of analyses, etc.
Limitations addressing sources of potential bias, changes to components,
imprecision of estimates, multiplicity of analyses etc. and changes to
pilot study protocol
21 Generalisability of the findings to other studies;
transferable information (external validity, applicability), etc.
Generalisability of pilot work to other studies; is larger trial needed;
transferable information (external validity, applicability), etc.
22a Interpretation consistent with results for each component
tested, balancing benefits and harms, and considering
other relevant evidence
Interpretation consistent with results for pilot study, balancing benefits
and harms, and considering other relevant evidence; will main trial go ahead;
how it will be designed
22b Assessment of feasibility of each component Changes to main study protocol
23 Not applicable Registration number and name of trial registry
24 Research review committee approval, ethics approval
and consent to participate
Research review committee approval, ethics approval and consent to participate;
where the trial protocol can be accessed, if available
25 Sources of funding and other support Sources of funding and other support
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progress. Based on the feedback from all the stakeholder
engagements and Delphi process results, we redrafted our
definitions, with feasibility as an overarching term, and we
agreed to focus on reporting guidelines for pilot/feasibility
RCTs as our next step. We finalized the draft list of items
for a reporting guideline to be discussed at the consensus
meeting. At this stage, we also confirmed with the CON-
SORT group that our checklist would be included as an of-
ficial CONSORTchecklist extension.
Consensus meeting: We held a 2-day meeting in Oxford,
UK, on October 27–28, 2014, to seek feedback on the
proposed items to be included in the guideline, and its
scope. We invited a group of international stakeholders
(n = 26) representing different professional sectors (aca-
demic, pharmaceutical, journal editors, publishers, fund-
ing bodies) and different clinical RCT roles (such as
trialists, methodologists, statisticians, and clinicians).
Using approaches that were similar to those used in pre-
vious consensus meetings for other guidelines [7, 9–20],
participants were presented in advance of the meeting with
the results of the literature review and the Delphi survey.
Working group members presented the background and an
update on work done to date, in order to facilitate the dis-
cussions. We also presented a penultimate version of the
checklist—based on the Delphi process and feedback from
the earlier stakeholder engagement meetings. The meeting
was audiotaped, and formal minutes were subsequently
prepared and circulated to all attendees.
The key recommendations that emerged were as follows:
 Modify items: It was recommended that 24 items
should be modified. These modifications were
primarily to prefix all references to “trial” with
“pilot” to clearly indicate that the information being
reported is about the pilot RCT, and not the main
RCT. As in previous CONSORT extensions [9–19],
some of the recommended changes begin with “if
relevant” or “when applicable”, to show that some
information which authors are being asked to report
might not be relevant or applicable for their
particular pilot RCT.
 Add new items: Four new items were suggested as
follows. Participants: how participants should be
identified and consented; outcomes: if applicable,
criteria used to judge whether, or how, to proceed
with a future definitive RCT; limitations:
implications for progression from the pilot to a
Fig. 2 An example of Delphi presentation for the two checklists
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future definitive RCT, including any proposed
amendments or modifications to the protocol
of the main RCT; and other information: if ethical
approval/research review committee approval was
confirmed, with a reference number.
 Remove items: It was recommended that, beyond an
item our group had already suggested, removing one
further item should be removed, Methods for
additional analyses, such as subgroup analyses and
adjusted analyses. Participants felt strongly that this
item was not applicable to pilot RCTs, because such
analyses would be about hypothesis testing or
generation—which is not the focus of a pilot RCT.
Part 5: write-up, dissemination, and implementation
Following the consensus meeting, we continued to refine
the content and wording of the items by virtual group dis-
cussion and by involving those who had attended the
meeting, to ensure they reflected the decisions that had
been made. There was second working group meeting in
London, UK, on January 12, 2015. We discussed the feed-
back from the consensus meeting in detail and outlined
strategies to complete the write-up of the guideline, in-
cluding plans for dissemination and implementation in
order to maximize its adoption by various journals, pro-
fessional associations and the clinical trial community.
As with previous guidelines [7, 9–20], our guideline
statement will be published with a detailed Explanation
and Elaboration (E&E) document that will provide an
in-depth explanation of the scientific rationale for each
recommendation, together with an example of clear
reporting for each item. We have sought feedback from
the consensus conference participants on the E&E docu-
ment to ensure that it accurately reflects the discussions
and decisions that were made during the meeting. To
widely disseminate the guideline, we will publish in
peer-reviewed journals and do presentations and work-
shops at conferences and other venues. We also plan to
seek endorsement of the guideline by journal editors.
Research has shown that formal endorsement and adop-
tion of the CONSORT Statement by journals is associ-
ated with improved quality of reporting [26]
Discussion
This article has described the methods and processes that
we have used to develop a CONSORT extension for
reporting of pilot/feasibility RCTs—using the 2010 version
of the CONSORT Statement as its basis [7]. The work
actually began with a broader mandate, to develop guide-
lines for feasibility and pilot studies. However, after receiv-
ing feedback from the research community, we have
started with a narrower focus of firstly developing a set of
guidelines for reporting feasibility and pilot RCTs. We
have attempted to use the best available and evidence-
based methods [21, 22], similar to those used by other
guideline developers [7, 9–20]. These include establishing
a working group to lead the project; conducting a system-
atic review of the literature to determine current practice
and identify available guidelines; applying an online Delphi
survey on the initial list of items to be included in the
guideline; holding a consensus meeting attended by vari-
ous stakeholders to finalize the list; and creating a dissem-
ination plan to enhance uptake for the guideline. In
addition, because of the perceived differences of opinion
about the definitions of feasibility and pilot studies, we
found that an ongoing discussion amongst the research
community over a considerable period was invaluable for
validating the direction of our work.
Table 2 The demographic characteristics of the main Delphi
study: n = 93
Demographic variables Levels Statistics: n (%)
Primary discipline/job title Statistician 53 (56.99 %)
Epidemiologist 2 (2.15 %)
Health service
researcher
13 (13.98 %)
Clinician scientist 4 (4.30 %)
Clinical trial
methodologist
5 (5.38 %)
Others 16 (17.20 %)
Country/region of residence UK 38 (40.86 %)
Europe 31 (33.33 %)
North America 23 (24.73 %)
Othersa 1 (1.08 %)
Key role in clinical trialsb Statistician 56 (60.22 %)
Methodologist 12 (12.90 %)
Principal/chief
investigator
27 (29.03 %)
Co-investigator 12 (12.90 %)
Trial manager 7 (7.53 %)
Research assistant 14 (15.05 %)
Experience in trials (years) 0–5 16 (17.20 %)
6–10 25 (26.88 %)
11–15 13 (13.98 %)
16–20 18 (19.35 %)
>20 21 (22.58 %)
Ever been involved in
write-up of study in
preparation for an RCT
Yes 61 (65.59 %)
No 32 (34.41 %)
aJapan
bLevels are not mutually exclusive
RCT randomized controlled trial
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In this paper, we have provided detailed descriptions
of the methods and processes that we used to develop
our guideline. These details are intended to provide
readers with enough information to assess the quality
and validity of the methods used to develop the CON-
SORT extension to pilot/feasibility RCTs guideline. We
applied approaches, methods, and processes that had
been used previously by guideline developers, to ensure
that the foundation for and development of our own
guideline was truly evidence-based. As with previous
guidelines [7, 9–19], we involved a wide spectrum of
stakeholders and participants representing different sec-
tors, perspectives, areas of expertise, and experiences with
trials—both in the Delphi process and the consensus
meeting. The participants in the Delphi surveys included
(bio)statisticians, clinicians, health services researchers,
regulatory staff, primary care practitioners, to mention a
few. A potential limitation is that the views of non-
statisticians may not have been adequately represented
since the majority of the participants were statisticians.
The participants in the consensus meeting came from dif-
ferent stakeholder groups representing professional sec-
tors (academic, pharma, journal editors, publishers,
funding bodies) and different clinical RCT roles (such as
trialists, methodologists, statisticians, and clinicians).
Prior to the consensus meeting, we had several Skype
and face-to-face discussions and presentations at sev-
eral professional conferences, to gather data and feed-
back. These steps were preceded by an extensive
review of the literature to assess the reporting of pilot
and feasibility trials.
We also spent a considerable amount of time debating
alternative definitions of feasibility and pilot trials, and
we used the Delphi study along with discussions at con-
ferences, and the expert consensus meeting, to get feed-
back on them. This led to the development of a
framework, in which pilot studies are viewed as a subset
of feasibility studies [26]. Within this framework, a feasi-
bility study is defined as a study asking “whether some-
thing can be done, should we proceed with it, and if so,
how” [26]. In contrast, “a pilot study asks the same ques-
tions but also has a specific design feature: in a pilot
study a future study, or part of a future study, is con-
ducted on a smaller scale” [26]. The framework and the
resulting definitions became essential elements in the
development process of the guideline.
We hope that our guideline will improve the reporting of
pilot/feasibility RCTs. We have already liaised with editors
of some key clinical journals, and we also plan to embark
on a campaign to get more journals to endorse the guide-
line. The intent is to target several groups: authors of jour-
nal manuscripts, who can use it as an outline for reporting
results of their pilot/feasibility RCTs; manuscript reviewers,
who can use it as template to evaluate reports of pilot/
feasibility RCTs; funding agencies, for use as a foundation
to create funding programmes for and evaluation of
pilot and feasibility RCT proposals; educators, for use
as a tool for training students and researchers about
the unique nature of pilot RCT methodology and
reporting; and end-users, for use as a tool to identify
relevant pilot RCTs—that provide evidence about
feasibility to inform their planning of main RCTs or
other pilot/feasibility RCTs.
Like all reporting guidelines, ours will require re-
evaluation and revisions over time—to ensure that it is
kept up to date with evolving research and knowledge
on pilot and feasibility trials.
One major outcome of this work is the setting up of a
new journal by BioMed Central, Pilot and Feasibility
Studies (http://pilotfeasibilitystudies.biomedcentral.com/),
which was launched on January 12, 2015. It provides a
platform for publishing these types of studies and consti-
tutes a much-needed place for researchers to share their
work and ideas on all aspects of the design, conduct, and
reporting of pilot and feasibility studies in health or bio-
medical research. While this is an important achievement
on its own, we hope that our guideline will also be a cata-
lyst for the establishment of better publication practices
and editorial policies regarding the reporting of pilot and
feasibility trials—a deficiency that has been noted previ-
ously [1, 3]. As of March 19, 2016, the new journal has re-
ceived over 70,000 unique web accesses, published 61
papers, of which 34 are protocols, 21 report the results of
pilot or feasibility studies/trials, and 6 are reviews, com-
mentaries, or methods papers. These statistics suggest that
investigators are indeed using the journal as an outlet for
publishing their pilot or feasibility works.
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